Avonex (recombinant IFN-β-1a) / Biogen  >>  Phase 2
Welcome,         Profile    Billing    Logout  

20 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Avonex (recombinant IFN-β-1a) / Biogen
NCT00001785: Recombinant Human Interferon Beta-1a (Avonex) for the Treatment of Patients With HTLV-1-Associated Myelopathy (HAM)

Completed
2
12
US
Recombinant human interferon beta-1a
National Institute of Neurological Disorders and Stroke (NINDS)
HTLV-I Infection, Spinal Cord Disease, Tropical Spastic Paraparesis
 
09/04
NCT00912860: Immunogenicity and Safety Study of Serum-Free Avonex

Completed
2
155
US
Interferon beta-1a, Avonex
Biogen
Multiple Sclerosis
12/04
01/05
NCT00099489: Safety and Efficacy of Avonex in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Completed
2
67
US, Canada, Europe, RoW
Interferon Beta-1a
Biogen
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
02/06
02/06
NCT00217295: A Safety Study of Combination Treatment With Avonex and Placebo-Controlled Dosing of Topamax in Relapsing-Remitting Multiple Sclerosis

Unknown status
2
30
US
Avonex and Topamax
Multiple Sclerosis Institute
Multiple Sclerosis
 
12/07
NCT00048347: Interferon-beta1a (AVONEX) Treatment of Ulcerative Colitis

Completed
2
18
US
AVONEX
National Institute of Allergy and Infectious Diseases (NIAID)
Ulcerative Colitis
06/08
05/10
NCT00324506: Safety and Efficacy of Cellcept and Avonex as Combination Treatment in Multiple Sclerosis

Completed
2
43
US
Mycophenolate Mofetil (CellCept)
University of Texas Southwestern Medical Center, Aspreva Pharmaceuticals
Multiple Sclerosis
06/09
06/09
NCT00489489 / 2006-003134-14: Phase II Study of Teriflunomide as Adjunctive Therapy to Interferon-beta in Subjects With Multiple Sclerosis

Completed
2
118
US, Canada, Europe
Teriflunomide, HMR1726, Placebo (for Teriflunomide), Interferon-β, Avonex®, Rebif®, Betaseron®
Sanofi
Multiple Sclerosis
06/09
06/09
NCT00616434 / 2007-004867-22: A Phase 2 Study of Interferon Beta-1a (Avonex®) in Ulcerative Colitis

Completed
2
123
US, Canada, Europe, RoW
BG9418 (Interferon beta-1a), Avonex®, Placebo
Biogen
Active Ulcerative Colitis
03/10
03/10
NCT00811395 / 2007-003997-24: Long Term Safety of Teriflunomide When Added to Interferon-Beta or Glatiramer Acetate in Patients With Multiple Sclerosis

Completed
2
182
US, Canada, Europe
Teriflunomide, HMR1726, Placebo (for teriflunomide), Interferon-β [IFN-β], Avonex®, Rebif®, Betaseron®, Glatiramer Acetate [GA], Copaxone®
Sanofi
Multiple Sclerosis
04/10
04/10
NCT00986960: Effect of Adrenocorticotropin Injection With Weekly Interferon Beta in Patients With Relapsing Remitting Multiple Sclerosis (MS)

Withdrawn
2
0
US
repository corticotropin injection, H.P. Acthar gel, Saline
University at Buffalo
Multiple Sclerosis
09/10
12/10
ONWARD, NCT00436826 / 2006-003366-33: A Phase 2 Study of Cladribine Add-on to Interferon-beta (IFN-beta) Therapy in Multiple Sclerosis (MS) Subjects With Active Disease

Checkmark EAN 2016: ONWARD
Jun 2016 - Jun 2016: EAN 2016: ONWARD
Checkmark AAN 2016: ONWARD
Mar 2016 - Mar 2016: AAN 2016: ONWARD
Checkmark AAN 2013
More
Completed
2
172
Europe, US, RoW
Cladribine, Placebo, Interferon-beta (IFN-beta), Avonex®, Betaseron®, RNF
EMD Serono Research & Development Institute, Inc.
Multiple Sclerosis
09/11
03/12
TERIVA, NCT01403376 / 2011-001160-21: Study to Investigate the Immune Response to Influenza Vaccine in Patients With Multiple Sclerosis on Teriflunomide

Checkmark AAN 2013
Jan 2013 - Jan 2013: AAN 2013
Completed
2
128
Canada, Europe, RoW
teriflunomide, HMR1726, Interferon-β-1, Rebif®, Avonex®, Betaseron®, Betaferon®, Extavia®, Genfaxone®, Influenza vaccine
Sanofi
Multiple Sclerosis
01/12
01/12
NCT00676715 / 2007-006338-32: A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis

Checkmark
Mar 2013 - Mar 2013: 
Checkmark AAN 2013
Jan 2013 - Jan 2013: AAN 2013
Checkmark Data AAN (MS)
More
Completed
2
220
Europe, Canada, US, RoW
Placebo, Ocrelizumab, RO4964913, Avonex, Interferon-beta-alpha1
Genentech, Inc., Roche Pharma AG
Multiple Sclerosis, Relapsing-Remitting
03/12
11/23
NCT00501943: Neuroprotection With Riluzole Patients With Early Multiple Sclerosis

Completed
2
43
US
Avonex (Interferon beta 1a), Riluzole, Placebo
University of California, San Francisco, National Multiple Sclerosis Society, Oregon Health and Science University
Multiple Sclerosis
10/12
10/12
SYNERGY, NCT01864148 / 2011-006262-40: Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex

Checkmark SYNERGY trial in RRMS
Sep 2016 - Sep 2016: SYNERGY trial in RRMS
Hourglass Sep 2016 - Sep 2016 : Presentation from the SYNERGY study at ECTRIMS
Checkmark SYNERGY trial
Jun 2016 - Jun 2016: SYNERGY trial
More
Completed
2
419
US, Canada, Europe, RoW
BIIB033, anti-LINGO-1 mAb, Placebo, Avonex, interferon beta-1a
Biogen
Multiple Sclerosis
12/15
03/16
2008-000256-26: An exploratory phase IIa study to evaluate the safety and immunological effects of intravenous interferonβ-1a (IFNβ-1a, Rebif®) therapy in the induction of tolerance to IFNβ in MS patients with neutralising antibodies (NAbs) to subcutaneous IFNβ-1a (Rebif® or Avonex®)

 
2
15
Europe
Mitoxantrone, PL 04515/0127, Mitoxantrone, Rebif®, Mitoxantrone, Rebif®
Queen Mary, University of London
Multiple Sclerosis
 
02/14
NCT01714089: Proof of Concept Study Evaluating RNS60 in the Treatment of Relapsing Remitting Multiple Sclerosis

Withdrawn
2
0
US
RNS60 125 ml, RNS60 250 ml, Interferon beta 1a
Revalesio Corporation
Relapsing Remitting Multiple Sclerosis
 
 
2016-002180-33: Multiple sclerosis therapy with transdermal myelin peptide stimulation.

Ongoing
2
220
Europe
SMderpept, Avonex, Powder for cutaneous solution, Solution for injection
Centrum Neurologii Krzysztof Selmaj, The National Centre for Research and Development
relapsing-remitting multiple sclerosis, multiple sclerosis, Diseases [C] - Nervous System Diseases [C10]
 
 
NCT04079088: Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) or Glatiramer Acetate in Relapsing Multiple Sclerosis (RMS)

Withdrawn
2
300
NA
Placebo, BIIB061, Interferon-beta1, Avonex, Plegridy, Betaferon/Betaseron, Extavia, or Rebif, Glatiramer acetate, Copaxone, Glatopa
Biogen
Relapsing Multiple Sclerosis
09/24
09/24
NCT05936229: Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy

Withdrawn
1/2
24
US
Interferon Beta-1A, 145258-61-3, Avonex, BG9418, Rebif, Recombinant interferon beta-1a, X-Ray Imaging, Conventional X-Ray, Diagnostic Radiology, Medical Imaging, Plain film radiographs, Radiographic Imaging, Radiographic imaging procedure (procedure), Radiography, RG, Static X-Ray, Echocardiography, EC, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Computed Tomography, CAT Scan, Computed Axial Tomography, Computerized axial tomography (procedure), Positron Emission Tomography, Pet Scan, Positron emission tomography (procedure), Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, Lumbar Puncture, LP, spinal tap, Bone Marrow Aspiration, Bone Marrow Biopsy, Biospecimen Collection, Biological Sample Collection, Biopsy, BIOPSY_TYPE, Bx
Fred Hutchinson Cancer Center, Faron Pharmaceuticals Ltd
Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B Acute Lymphoblastic Leukemia, Refractory B-Cell Non-Hodgkin Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
10/27
10/27

Download Options